Skip to content
The Policy VaultThe Policy Vault

Sirturo (bedaquiline)Point32Health

treatment-intolerant/nonresponsive multidrug-resistant (MDR) tuberculosis

Initial criteria

  • Documented diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) OR documented diagnosis of pulmonary extensively drug resistant (XDR) or treatment-intolerant/nonresponsive multidrug-resistant (MDR) tuberculosis
  • Prescribed by infectious disease specialist or pulmonologist
  • Sirturo will be used in combination therapy with at least three other antitubercular drugs OR will be used in combination therapy with Pretomanid and Zyvox (linezolid)

Approval duration

6 months